![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » NASTECH RESPONDS TO FDA LETTER FOR NASAL SPRAY ANDA
NASTECH RESPONDS TO FDA LETTER FOR NASAL SPRAY ANDA
Nastech Pharmaceutical announced it has submitted a complete response to the not approvable letter from the FDA for its abbreviated new drug application (ANDA) for a generic nasal treatment for osteoporosis. The response addresses the potential for immunogenicity that might result from a possible interaction between calcitonin-salmon and chlorobutanol, the preservative in Nastech's calcitonin-salmon nasal spray formulation.
Nastech's response consists of an extensive comparison of Nastech's product with the innovator drug, Novartis' Miacalcin, using multiple analytical and bio-analytical methods. Neither peptide-preservative interactions nor peptide-peptide aggregation were affected by a change in preservative by any method evaluated. Data obtained using numerous measurement techniques indicate that there is no evidence of a structural or conformational change in the peptide, and no increase in the potential to aggregate as a result of the preservative change. Finally, both immunoassay and bioassay studies indicate no difference associated with either preservative or an absence of preservative in the formulation.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct